Magnificamide Is a New Effective Mammalian α-Amylase Inhibitor

O. V. Sintsova; E. V. Leychenko; I. N. Gladkikh; A. P. Kalinovskii; M. M. Monastyrnaya; E. P. Kozlovskaya

doi:10.1134/S1607672919060097

Magnificamide Is a New Effective Mammalian α-Amylase Inhibitor

Autores: Sintsova O.V.¹, Leychenko E.V.¹, Gladkikh I.N.¹, Kalinovskii A.P.¹^,2, Monastyrnaya M.M.¹, Kozlovskaya E.P.¹
Afiliações:
1. Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch, Russian Academy of Sciences
2. School of Natural Sciences, Far Eastern Federal University
Edição: Volume 489, Nº 1 (2019)
Páginas: 385-387
Seção: Biochemistry, Biophysics, and Molecular Biology
URL: https://journals.rcsi.science/1607-6729/article/view/213120
DOI: https://doi.org/10.1134/S1607672919060097
ID: 213120

Citar

Texto integral

Acesso aberto
Acesso é fechado

Acesso está concedido
Acesso é fechado

Somente assinantes

Resumo
Sobre autores
Bibliografia
Arquivos suplementares
Estatísticas

Resumo

Recombinant analogue of the sea anemone Heteractismagnifica peptide was obtained, and the kinetic parameters of its interaction with mammalian α-amylases were determined. Magnificamide inhibits α-amylases significantly stronger than the medical drug acarbose (Precose^TM or Glucobay^TM). Magnificamide is assumed to find application as a drug for prevention and treatment of metabolic disorders and type 2 diabetes mellitus.